Akari Therapeutics Reports Positive Preclinical Data for Cancer Therapy
Akari Therapeutics (AKTX) announced promising preclinical data showing its lead cancer therapy AKTX-101 demonstrates strong synergistic tumor-killing activity when combined with KRAS inhibitors in pancreatic cancer models. The news led to a significant rise of over 120% in the company's stock price during extended trading.
Topics: biotech cancer therapy drug development stock movement